Bio-Path (BPTH) Trading 5% Higher

Bio-Path Holdings, Inc. (NASDAQ:BPTH)’s share price traded up 5% on Wednesday . The company traded as high as $0.23 and last traded at $0.21. 660,607 shares changed hands during mid-day trading, an increase of 50% from the average session volume of 440,947 shares. The stock had previously closed at $0.20.

Several equities analysts have recently commented on BPTH shares. HC Wainwright reiterated a “buy” rating and set a $1.50 price objective (down from $4.50) on shares of Bio-Path in a research report on Monday, November 13th. reduced their price objective on Bio-Path from $4.50 to $1.50 and set a “buy” rating on the stock in a research report on Wednesday, November 15th. Finally, ValuEngine lowered Bio-Path from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $1.67.

The firm has a market cap of $22.68, a price-to-earnings ratio of -3.00 and a beta of 2.92.

Bio-Path (NASDAQ:BPTH) last released its earnings results on Thursday, November 9th. The company reported ($0.02) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.02). equities research analysts anticipate that Bio-Path Holdings, Inc. will post -0.08 EPS for the current year.

Large investors have recently made changes to their positions in the business. Sabby Management LLC raised its stake in Bio-Path by 73.2% during the second quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock valued at $462,000 after buying an additional 503,488 shares during the last quarter. HighTower Advisors LLC raised its stake in Bio-Path by 0.3% during the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Bio-Path by 5,474.3% during the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares during the last quarter. Institutional investors and hedge funds own 9.36% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Bio-Path (BPTH) Trading 5% Higher” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

Bio-Path Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

What are top analysts saying about Bio-Path? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bio-Path and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit